Abbott India (ABBOTINDIA.NS) Stock Price
Abbott India Price
Over the last 19 years Abbott India grew revenue by 14.7% annually, reaching 69.29 B INR. Earnings per share have grown at 18.7% per year over the last 19 years. For Abbott India, the net margin of 22.4% is up versus 16.3% a few years ago. At today's price the dividend yield works out to roughly 1.79%. The payout ratio is around 61% of earnings. The dividend has grown at 19.0% per year over the past 19 years. The consensus 12-month price target for Abbott India is 37,740.00 INR, about 42.2% above where the stock trades today. Of 12 analysts, 11 rate the stock a buy — an overall Buy consensus.
Abbott India stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Abbott India business model & stock analysis
Frequently asked questions about Abbott India
Abbott India Ltd operates as a leading pharmaceutical company in India. The company's business model primarily focuses on developing, manufacturing, and selling a wide range of healthcare products including pharmaceuticals, diagnostics, nutritional products, and medical devices. Abbott India Ltd follows a diversified approach by serving various therapeutic segments such as neuroscience, gastroenterology, women's health, cardiovascular, metabolic disorders, and more. The company strives to provide innovative and high-quality healthcare solutions to improve the lives of people in India. Abbott India Ltd continuously invests in research and development to bring new and advanced products to the market, reinforcing its position as a trusted and reliable pharmaceutical company.
Abbott India Ltd is primarily active in the pharmaceutical industry. As a leading player in the healthcare sector, Abbott India Ltd focuses on manufacturing and marketing a wide range of pharmaceutical products across multiple therapeutic categories. With its commitment to delivering high-quality healthcare solutions, Abbott India Ltd has established its presence in areas such as gastroenterology, women's health, neuroscience, and cardiovascular care. Through its innovative and diverse product portfolio, Abbott India Ltd strives to improve the lives of patients and contribute to the overall well-being of people in India.
The main competitors of Abbott India Ltd in the market include pharmaceutical companies such as Sun Pharmaceutical Industries Ltd, Cipla Ltd, and Dr. Reddy's Laboratories Ltd. These companies also operate within the Indian pharmaceutical market and offer a range of products and services similar to Abbott India Ltd. However, Abbott India Ltd distinguishes itself through its innovative product portfolio, strong brand reputation, and commitment to research and development.
Abbott India Ltd is a leading pharmaceutical company with a rich history and background. Established in India in 1944, Abbott India has been an integral part of the Indian healthcare sector for over 75 years. The company is a subsidiary of Abbott Laboratories, a global healthcare conglomerate based in the United States. Abbott India Ltd focuses on providing high-quality pharmaceutical products across various therapeutic areas, including neuroscience, gastroenterology, women's health, and cardiovascular diseases. With a strong commitment to innovation, research, and development, Abbott India Ltd has emerged as a trusted name in the Indian pharmaceutical industry, dedicated to improving people's lives through its wide range of healthcare solutions.
Abbott India Ltd has achieved several significant milestones throughout its existence. One noteworthy milestone was the company's establishment in India in 1910, showcasing its long-standing presence in the country. Another important achievement was the successful rebranding and divisional integration with Abbott Laboratories, a global healthcare leader. Additionally, Abbott India Ltd has consistently emerged as a reliable and innovative player in the pharmaceutical and healthcare industry, introducing various breakthrough products and technologies. The company's commitment to quality and patient care has earned it several accolades and certifications, further cementing its strong reputation in the market.
Abbott India Ltd is primarily present in India.
Abbott India Ltd represents a strong set of values and a customer-centric corporate philosophy. The company is committed to improving lives by providing high-quality healthcare products and services. Abbott India focuses on innovation, integrity, and excellence in all its operations, striving to make a positive impact on the healthcare industry. With a customer-driven approach, the company leverages advanced technologies and research to develop and deliver safe and effective healthcare solutions. Abbott India Ltd aims to be a trusted partner in meeting the diverse healthcare needs of the Indian population, reinforcing its commitment to improving overall well-being and driving sustainable growth.
Analysts currently set an average price target of 37,760.40 INR for the Abbott India stock (median: 37,740.00 INR), implying +42.3 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Abbott India stock: 11 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Abbott India share trades at 255.06 EUR (26,535.00 INR).
Abbott India Limited is a leading healthcare company focused on the development and marketing of medical devices, medical diagnostic tools, and pharmaceuticals. The company is headquartered in Mumbai and is a subsidiary of Abbott Laboratories, a global provider of healthcare products. Abbott India operates several business segments, including pharmaceuticals, medical devices, and diagnostics. It is involved in the pharmaceutical industry and offers a wide range of medications for various therapeutic areas such as gastrointestinal disorders, heart diseases, pain management, and antibiotics. The company works closely with its research and development teams to develop innovative medicines for patients worldwide. Abbott India Limited is also a leading provider of medical diagnostic tools, offering a wide range of diagnostic and screening solutions for various diseases such as HIV, hepatitis, diabetes, and cancer. Its products include blood glucose and cholesterol testing devices, rapid tests for infectious diseases, and various laboratory diagnostics. The company's diagnostics division is dedicated to improving healthcare through affordable and accessible testing solutions for a wider population. In addition to offering medications and diagnostic tools, Abbott India is also a leading provider of medical devices and equipment. The company offers a wide range of medical devices for various therapeutic areas, including artificial joints, cardiac implants, stents, and pacemakers. Additionally, the company also provides homecare products, including ventilators and insulin pumps, to enable convenient and cost-effective care for patients. Abbott India Limited strives to improve access to healthcare products and services through innovative business models. It works closely with healthcare providers, physicians, and government agencies to strengthen the healthcare system and improve treatment options. The company also offers various programs and initiatives to enhance patient care, including training and workshops for healthcare professionals to improve patient care. Overall, Abbott India is a leading provider of healthcare products and services focused on improving healthcare in India and globally. The company offers a wide range of medications, medical devices, and diagnostic tools, as well as training programs and initiatives to improve healthcare. Abbott India remains committed to developing innovative solutions and helping patients worldwide lead better lives.
The revenue of Abbott India is 69.29 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Abbott India is 15.52 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Abbott India is currently 36.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Abbott India stock.
The price-to-sales ratio (P/S) of Abbott India is currently 8.14. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Abbott India stock.
The Eulerpool Quality Score for Abbott India is 10/10.
The ISIN of Abbott India is INE358A01014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Abbott India is ABBOTINDIA.NS. The ticker symbol is used to trade Abbott India shares on the stock exchange.
Abbott India stock
Abbott India Peer Group
Abbott India FIGI
All fundamentals and in-depth analysis of Abbott India
Our stock analysis for Abbott India stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abbott India. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.